Kyverna Therapeutics, Inc. KYTX EBITDA

EBITDA at other companies

Bristol-Myers SquibbBMY

$4.68B+68.1%

Gilead SciencesGILD

-$10.3B-501%

Climb Bio, Inc.CLYM

-$15.17M+34.1%

Artiva Biotherapeutics, Inc.ARTV

-$26.2M-18.2%

Iovance Biotherapeutics, Inc.IOVA

-$48.12M+56.4%

Allogene TherapeuticsALLO

-$43.22M+30.4%

FAQ

What is Kyverna Therapeutics, Inc.'s EBITDA?

Kyverna Therapeutics, Inc. (KYTX) reported EBITDA of -$41.02M in Q1 2026.

How has Kyverna Therapeutics, Inc.'s EBITDA changed year-over-year?

Kyverna Therapeutics, Inc.'s EBITDA increased by 12.6% year-over-year, from -$46.91M to -$41.02M.

What is the long-term trend for Kyverna Therapeutics, Inc.'s EBITDA?

Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s EBITDA has grown at a 66.4% compound annual growth rate (CAGR), from -$60.7M to -$168.03M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.